Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Gamma Knife surgery (GKS) for brain metastasis (BM) has been generally advocated for patients with a Karnofsky performance status (KPS) scale of ≥ 70. However, some patients with a poor KPS scale of < 70 are recoverable after GKS and show durable survival. A purpose of this study is to devise a 3-month survival prediction model to screen patients with BM with a KPS of ≤ 70 in whom GKS is needed. A retrospective analysis of 67 patients with a KPS scale of 60-70 undergoing GKS for BM of non-small cell lung cancer (NSCLC) from 2016 to 2020 in our institute was performed. Univariate and multivariate logistic regression analyses were performed to investigate factors related to survival for more than 3 months after GKS. The probability (P) prediction model was designed by giving a weight corresponding to the odds ratio of the variables. The overall survival was 9.9 ± 12.7 months (range 0.2-53.2), with a 3-month survival rate of 59.7% (n = 40). In multivariate logistic regression analysis, extracranial disease (ECD) control (p = .033), focal neurological deficit (FND) (p = .014), and cumulative tumor volume (∑ TV) (p = .005) were associated with 3-month survival. The prediction model of 3-month survival (Harrell's C index = 0.767) was devised based on associated factors. In conclusion, GKS for BMs is recommended in selected patients, even if the KPS scale is ≤ 70.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423256PMC
http://dx.doi.org/10.1038/s41598-023-40356-6DOI Listing

Publication Analysis

Top Keywords

gamma knife
8
knife surgery
8
brain metastasis
8
karnofsky performance
8
kps scale
8
3-month survival
4
survival model
4
model gamma
4
surgery patients
4
patients brain
4

Similar Publications

Introduction Stereotactic radiosurgery (SRS) is widely regarded as the standard of care after the resection of brain metastases in order to reduce local cavity recurrence risk. The objective of this study was to explore the reproducibility of published outcomes for patients receiving post-operative stereotactic radiosurgery (cavity SRS) in a National Health Service (NHS) setting for a non-selective series of patients. For our service, the median interval between surgery to cavity SRS (cSRS) is eight weeks, whereas similar timelines have been found to have a deleterious impact on survival in the published literature.

View Article and Find Full Text PDF

Background: Stereotactic Body Radiotherapy (SBRT) has been proven to be a safe and effective alternative to surgery in patients with metastatic primary sarcoma. However, data describing tumor response in relation to the given radiotherapy dose is lacking. Therefore, this study aims at analyzing efficacy and dose-response relationship in a retrospective cohort.

View Article and Find Full Text PDF

Introduction: Radiosurgery targeting the thalamus has long been used to treat refractory pain, with medial thalamotomy as a key approach. Traditionally, targeting relied on indirect methods based on anatomical atlases, which do not account for individual variations in brain connectivity. Recent advances in connectomic-guided stereotactic radiosurgery have improved precision in the treatment of movement disorders, but their application to pain management remains underexplored.

View Article and Find Full Text PDF

While World Health Organization (WHO) grade I meningiomas are typically slow growing and associated with favorable prognoses, a subset may exhibit unexpectedly aggressive behavior and resistance to conventional treatment approaches. Recurrent grade I meningiomas, in particular, are associated with a poorer prognosis despite their benign histological classification, underscoring the need for advanced genomic and radiomic analyses to refine diagnostic accuracy. We present a case of a 52-year-old female with a grade I parafalcine meningioma initially deemed nonaggressive, but ultimately recurred multiple times over several years despite undergoing repeated craniotomies and several courses of radiosurgery.

View Article and Find Full Text PDF

Management of recurrent adenoid cystic carcinoma (ACC) in elderly patients remains challenging due to comorbidities, functional impairments, and anatomically complex tumor locations that complicate surgical access and increase operative risk. The ZAP-X Gyroscopic Radiosurgery System (ZAP Surgical Systems, Inc., San Carlos, CA, USA) offers a highly precise, non-invasive treatment modality, potentially suitable for salvage therapy in previously irradiated fields and in medically inoperable patients.

View Article and Find Full Text PDF